Key points are not available for this paper at this time.
Iptacopan (LNP023) is an oral, first-in-class, low molecular weight inhibitor of Factor B in clinical development for the treatment of diseases associated with activation of the alternative complement pathway. Phase 3 studies of iptacopan are ongoing in paroxysmal nocturnal hemoglobinuria, C3 glomerulonephritis, IgA nephropathy, and atypical hemolytic uremic syndrome. The pharmacokinetics (PK) of oral iptacopan were measured in healthy subjects to determine its capacity to deliver therapeutic (∼1000 ng/mL) systemic exposure.
Schmouder et al. (Mon,) studied this question.